Cardiology

Results of the phase 3 trial show that inclisiran reduced LDL cholesterol in patients with atherosclerotic cardiovascular disease.

A smartwatch and patch product from Biobeat will allow physicians and patients to monitor blood pressure, oxygenation, and heart rates in both inpatient and outpatient settings.

A recent study from South Korea is shedding light on the association of blood pressure levels and cardiorenal events.

A study from ESC 2019 found the occurrence of ACS was more common in winter months and heavily polluted cities after examining more than 15,000 patients from across Poland.

A 600-city analysis of particulate matter found daily exposure is linked to worsened mortality rates, particularly in areas with higher mean temperatures.

Results of the PolyIran study, which examined more than 6000 patients, found that use of a polypill reduced the risk of major cardiovascular events.

National Institute of Health Research study found that physicial activity, even for just 24 minutes per day, was associated with reduced risk of all-cause mortality.

A recent analysis of the Asian Sudden Cardiac Death in Heart Failure registry found that type 2 diabetes mellitus was associated with structural changes of the heart and poorer quality of life.

A pattern of poor sleep could lead to worsened psychiatric wellbeing—and eventually, memory loss.

Findings from the Insight 46 study reveal blood pressure changes during midlife can lead to poorer brain health as a patient gets older.

Stacy Brethauer, MD, will lead discussion on the influence of BMI on bariatric surgery, and the influence of obesity on public health.

Analysis of the Framingham Heart Study found that while quitting smoking lowers a person's CVD risk, that risk may not return to normal for up to 25 years.

Investigators from the University of Pennsylvania found that negative effects of vaping on blood vessels can be noted after a single use.

Clinicians have indicated which symptom subtypes are associated with a greater risk of cardiovascular conditions in patients with OSA.

The new device will treat patients who are not suited for other commonly used treatment options for advanced heart failure.

Children and adolescents have considerably fewer control therapy options for T2D. The GLP-1 agonist could be the first of its class for pediatric indication.

The TAVR treatment was associated with a 46% reduction in one-year event risk among patients at low risk of open heart surgery.

While results of COMPASS proved the efficacy of combination rivaroxban-plus-aspirin, it may not be the best treatment for every patient suffering from coronary or peripheral artery disease.

A team of investigators review global HCV infection rates in an attempt to quantify HCV-associated cardiovascular disease.

After showing a significant impact on reduction of cardiovascular events, a slew of subgroup analyses were performed examining use of icosapent ethyl using data derived from REDUCE-IT.

The investigative monoclonal antibody from Regeneron shows significant benefit for patients with the rare, severe homozygous familial hypercholesterolemia.

Trial investigator Deepak Bhatt, MD, MPH, discusses how use of rivaroxaban in a clinical setting has changed as a result of the COMPASS trial.

Lead investigator of REDUCE-IT trials discusses the impact of trial results and what that means for EPA-based treatments going forward.

Use of rivaroxaban (Xarelto) plus aspirin was found to reduce cardiovascular and major limb events in a secondary analysis of the COMPASS trial.

How do the states with the longest-running legislation permitting MAID compare?

The committee meeting, tentatively scheduled for November 14, will have to precede the sNDA PDUFA action date set to review the drug's potential indication for reducing residual cardiovascular risks in patients with elevated triglycerides.